First human test for potential cheaper psoriasis treatment
NCT ID NCT07258745
Summary
This early-stage study aims to see if a new, potentially lower-cost version of the psoriasis drug Skyrizi (called CKD-704) behaves similarly in the body. It will compare how healthy adults process a single dose of the new drug versus the original versions from the US and Europe. The main goal is to check if the new version has similar drug levels in the blood and is equally safe and well-tolerated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MTZ powered by Pratia
RECRUITINGWarsaw, Warszawa, 02-172, Poland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.